Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,160 Cr
verified against source
Revenue YoY
14.8%
reported change
EBITDA
₹147 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations. EBITDA margin expanded 65 bps YoY to 12.7%, aided by operating leverage and cost controls. PAT grew 2.1% to ₹68 crore, impacted by a one-time labor code charge of ₹18.2 crore. Management highlighted broad-based volume growth across therapies and channels, with Q4 also expected to see double-digit volume growth. Key growth drivers include the EU CDMO contract (€35M annual run-rate from FY28) and Zambia project ($25M supplies from H1 FY27). Risks include sustained API pricing pressure and potential delays in regulatory approvals for new facilities.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects continued double-digit volume growth in CDMO for Q4 FY26 based on current visibility.
- The EU CDMO contract is expected to generate annual revenue of €35 million once commercial supplies begin, with supplies starting in FY28.
- Commercial supplies of $25 million from Indian plants to Zambia expected in H1 FY27, with similar amount in FY28.
- Capital expenditure for FY27 is expected to be consistent with past levels, focusing on maintenance and modernization.
Risks flagged
- API business continues to face pricing softness across key molecules, though the pace of decline has moderated.
- The injectables facility is still ramping up with low utilization; delays in client audits or approvals could impact revenue contribution.
- Trade generic revenue declined 18% YoY and remains loss-making; management expects some bottom-line impact in Q4.
- Analyst questioned whether the strong volume growth is sustainable; management cited market share gains but acknowledged it's market-driven.
Key quotes
- Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.
- So the recovery has come both in terms of margins as well as in terms of topline to us and the recovery looks stable as of now.
- We continue to work towards reducing losses in the trade generic and API segment by way of portfolio rationalization and tighter control over overheads.
Research modules